Background: Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors for some of which the epithelial growth factor receptor (EGFR) pathway may play an important role. We investigated the efficacy and toxicity of an anti-EGFR antibody ( panitumumab) combined with a standard neoadjuvant anthracycline-taxane-based chemotherapy in patients with operable, stage II-III, TNBC.
introduction Triple-negative breast cancer (TNBC) is defined by negativity of estrogen and progesterone receptors (ER/PR) and the lack of human epidermal growth factor 2 (HER2) overexpression [1] . TNBC are heterogeneous, but in majority basal-like (71%-91%), with overexpression of 'basal' keratins and/or epithelial growth factor receptor (EGFR). In contrast, treatments remain monolytic, based on chemotherapy.
Neoadjuvant chemotherapy (NACT) is emerging in the management of operable TNBC, confirmed by the correlation between pathologic complete response ( pCR) and survival [2] . With taxane/anthracycline-based chemotherapies, pCR rates range from 12% to 39%. Consequently, research focused on chemotherapy optimization and biologic modifiers.
Considering EGFR abnormalities in TNBC (27%-57%), anti-EGFR monoclonal antibodies (MoABs) or tyrosine kinase inhibitors (TKIs) were investigated in metastatic setting [3] . While panitumumab is presently tested in phase II (ClinicalTrials.gov NCT01009983), cetuximab was shown to improve progressionfree survival (P = 0.032) [4] . In contrast, TKIs displayed a modest activity in phase II trials [5] .
Currently, no study investigated anti-EGFR MoAB with NACT in BC. Panitumumab-epidoxorubicin (E) showed a greater potency against mammary carcinoma than epidoxorubicin alone, but no data are available with docetaxel (T) or 5-fluorouracil (F) [6] .
Consequently, we investigated panitumumab with an anthracycline/taxane NACT for operable TNBC [7] .
materials and methods

study design
This multicentric neoadjuvant phase II trial evaluated the efficacy and toxicity of panitumumab with FEC followed by T for operable TNBC.
The main end point was pCR in assessable patients (Chevallier classification) [8] . Secondary end points were: pCR (Sataloff classification), clinical CR (cCR) and toxicity [9] . Exploratory end points aimed at identifying predictive biomarkers of therapeutic efficacy and resistance. eligibility criteria Eligibility criteria were: age >18 years; performance status ≤2 [World Health Organization (WHO) criteria]; histologically confirmed breast adenocarcinoma; negative hormonal receptors (HR) (immunohistochemistry: <10%) [1, 10] ; absent HER2 gene amplification by in situ hybridization [11, 12] ; clinical stage II/IIIa; normal cardiac function; adequate biology; no prior surgery/chemo/hormonal/anti-EGFR and radiation therapy.
Non-eligibility criteria were: non-measurable tumor; pulmonary fibrosis; significant neurologic/psychiatric abnormalities; peripheral neuropathy ≥grade 2 and concomitant experimental drug.
The study and written informed consent forms were approved by the regional ethical committee. The trial complied with the Declaration of Helsinki and the provision of the Good Clinical Practices guidelines. Each participating center obtained approval from their institutional review board. All patients received oral and written information before providing a written consent.
study treatment
Patients received eight panitumumab (9 mg/kg) intravenous cycles combined with FEC × 4 (500/100/500 mg/m 2 ), followed by T × 4 (100 mg/m 2 ).
Prophylactic antiemetics/corticosteroids, continuous doxycycline (200 mg/day) and topical treatments were systematic.
All patients underwent surgery/radiotherapy according to the institutional guidelines. Patients with residual tumor were allowed additional therapy.
toxicity and dose modifications
Toxicities were assessed using the Common Terminology Criteria for Adverse Events (NCI-CTCAE version 3.0).
For grade 3/4 skin toxicities, panitumumab was postponed until recovery ≤grade 2 within 3 weeks (two successive 20% dose decreases) and discontinued beyond 3 weeks. Chemotherapy (CT) was delayed until recovery for grade ≥2 hematological toxicities. In case of febrile neutropenia, patients received prophylactic granulocyte colony-stimulating factor. For grade ≥3 non-hematological toxicities, CT doses were reduced (25%) and discontinued if reoccurrence.
study evaluations
Screening assessments included medical history, clinical examination, complete laboratory tests, bilateral senologic exams (mammography/ultrasound), metastatic work-up, tumor core biopsy and, if indicated, fine-needle aspiration of palpable lymph nodes. Additional clinical/senologic measurements were carried out every two cycles and before surgery. Clinical response was assessed according to WHO criteria.
Formalin-fixed paraffin-embedded (FFPE) and frozen tumor samples were collected before and after NACT, for central histological review and biomarker studies. [13] .
Pathological response was assessed using Chevallier and Sataloff classifications, pCR, respectively, defined as classes 1/2 and TANA/TANB [8, 9] .
EGFR, insulin growth factor 1-receptor (IGF1-R), cytokeratins 5/6 and 8/ 18 (CK5/6 and CK8/18), the number of FOrkhead boX P3 (FOXP3)-positive (FOXP3+) and CD8 antigen-positive (CD8+) tumor-infiltrating lymphocyte (TIL) analyses were carried out on FFPE pre-therapy biopsies (Benchmark XT automates, UltraView DAB visualization systems; Ventana, Tucson, AZ) [14] . Two independent pathologists evaluated semi-quantitatively EGFR and IGF1-R expressions using Quick-score (Q-score). Antibodies, scoring systems and the cutoffs are listed in Table 1 . The FOXP3+ and CD8+ TIL counts were determined on five consecutive high-pass filter (HPF) (×400), using a Nikon Eclipse 50i microscope.
For BRCA1 mutations, we used the sequencing Sanger method on a 3130XL capillary electrophoresis system (Applied Biosystems) and alignment to the reference sequences with the Seqman software (DNA Star, Inc., Madison, WI). EGFR (exons 15, 18, 19, 20, 21 and 24) mutational analyses were done by pyrosequencing with a 454 GS-FLX automate/Amplicon Variant Analyzer software (Roche) .
sample size and statistical considerations
Sample size was calculated on a 25% absolute increased pCR rate beyond 20% (CT alone), α = 5% and β = 20% and one-sided test. Statistical analysis used the SEM software [16] .
All proportions/frequencies used 95% confidence interval (95% CI). The relationship between factors and pCR was evaluated by χ 2 test, Student's t-test or Mann-Whitney U-test, and correlations between two quantitative variables with Spearman ranks correlation coefficient. Receiver operating characteristic curves established thresholds of biomarkers for response. P-values <0.05 were considered significant. A complementary analysis was carried out (Quinten, Paris, France) using a non-parametric supervised clustering algorithm (Q-Finder) without assumption regarding outcome distribution or explanatory variables. Categorical and continuous variables were explored simultaneously. A set of rules was defined as a combination of variables predicting a subcohort with higher-than-average proportion of pCR patients. The maximum variables per rule was 2 to keep them biologically understandable. The selection of rules was determined by the size of patients per rule and a hypergeometrical P-value and 95% CI.
results patients and tumor characteristics
Sixty patients were included with following characteristics: median age, 50 years; premenopausal women, 60%; tumor median clinical diameter, 40 mm; T2, 76.7%; N1-2, 35%; (Table 2) .
treatment disposition
Thirteen patients were excluded from the analysis (3 non-TNBC and 10 with progressive disease or grade 3-4 toxicities) (Figure 1 safety Neutropenia grade 4 and febrile neutropenia were reported, respectively, in 20.5% and 3.6% of cycles with no documented infection. Non-hematological toxicities were manageable (Table 4) with mainly cutaneous toxicities including grade 3 and 4 acneiform rashes (35% and 8.3%, respectively), grade 3 dry skin (10.0%) and erythema (5.0%). No significant correlation was found between skin toxicity and pCR (P = 0.76). No toxic deaths were reported.
follow-up
With 33-month median follow-up [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] , nine relapses (1 local and 8 metastatic) occurred mostly during the first-year post-therapy ( patients <55 years with tumors >40 mm). Two pCR patients (9%) relapsed in the brain only (still alive) contrasting with seven non-pCR patients (24%), six of them with brain or visceral metastases lethal within 6 months.
mutation frequencies
Five patients were germline BRCA1 mutation carriers. EGFR single-nucleotide polymorphisms (SNPs) were found in several patients (Table 5) .
predictive factors for pCR
Pre-treatment biopsy analyses identified several predictive factors for pCR: EGFR and IGF1-R high expression, low number of CK8/ 18+ tumor cells and high CD8+ TIL count. By univariate analysis, IGF-1R high expression (Q-score >90) led to a 89% pCR rate versus 33% for low expression (Q-score ≤90) (P = 0.028). Other biomarkers correlated with pCR were EGFR levels and the fraction of CK8/18+ tumor cells. High EGFR expression (Q-score >70) showed a trend for pCR (58% versus 28%, P = 0.079). 
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When EGFR expression was combined with the percentage of CK8/18+ tumor cells, pCR was achieved in 86% of tumors with low CK8/18 (<20%) and high EGFR histoscore ≥80 compared with other subpopulations with pCR ranging from 9% to 43% (P = 0.0002) (Figure 2 ). Additionally, a CD8+ TIL count ≥118 was highly predictive of pCR compared with patients with <118 CD8+ TIL (84% versus 10%; relative risk = 8.4; P = 0.000003). discussion This is the first multicentric prospective neoadjuvant phase II trial investigating the efficacy and toxicity of a standard chemotherapy with panitumumab in TNBC.
With pCR rates of 46.8% (Chevallier) and 55.3% (Sataloff ) in assessable patients, we confirmed our scientific hypothesis (25% absolute increase in pCR >20%). However, the ITT analysis showed a pCR rate of 40.3%. In the literature, sequential taxane/ anthracycline chemotherapies yield pCR rates ∼ 20% [17] . Only dose-dense or dose-intensive regimens led to pCR rates of 34%-38% [18, 19] .
Several authors have stressed the importance of strictly defining pCR as ypT0ypN0 excluding ductal carcinoma in situ (Chevallier class 1) [2] . This stricter definition was not used in our study as pCR was based on Chevallier classes 1 + 2.
Clinical/mammographic CR rates were 77.7% and 59.2%, respectively, contrasting with 35.7% by ultrasound, confirming the poor value of clinical/mammographic assessments and suggesting that careful ultrasound analysis appears the most reliable pCR predictor in neoadjuvant strategies.
The safety profile was as expected. With panitumumab, the most frequent toxicity was cutaneous [4] . Skin toxicity was more frequent with docetaxel than FEC and was overall manageable using prophylactic measures.
The patterns of relapse are consistent with the literature emphasizing a high prevalence of brain metastases in TNBC (50% in our trial) with shorter median overall survival (OS) compared with other BC subtypes. As in our series, Heitz et al. [20] reported an increased risk for patients <55 years with large tumors, early relapses (usually first-year post-therapy) and <6 months OS. Among our pCR patients, we observed two distant relapses (brain only-9.0%), both still alive, contrasting with six relapses (cerebral/visceral) in non-pCR patients (24%), all deceased within 6 months. Several authors confirmed the strong predictive value of pCR for TNBC outcome [17] .
In our cohort, BRCA1 mutations were unfrequent (10.8%), as opposed to EGFR SNPs (Table 5) . No correlations were found with tumor clinicopathological features or patient outcome, known to be similar between sporadic and BRCA1-mutated TNBC (BRCAness phenotype) [21] . In keeping with the literature, no EGFR mutations were recorded, even within the usual hotspots (exons 15/18/19/20/21) [22, 23] . We did not evaluate an EGFR gene copy number in this study; however, Park et al. [24] found that the EGFR copy number was associated with poor outcome in TNBC, suggesting that the EGFR copy number could be useful for selecting patients for anti-EGFR therapy.
Our strongest predictor for pCR was not tumoral but immunological as high CD8+ TIL count led to a 84% pCR rate. The role of tumor microenvironment in BC was recently stressed by Denkert et al. [25] , reporting that CD3+ or CD20+ TIL was independent pCR predictors. However, data on the significance of TIL profile in TNBC are still scarce. West et al. [26] showed, in HR-negative BC, a correlation between high cytotoxic TIL and increased sensitivity to CT. In our study, high IGF-1R alone was also a strong predictive for pCR (89%). The correlation between high tumor IGF-1R expression and pCR is controversial, as only one study reported an increased sensitivity to an IGF-1R inhibitor in TNBC cell lines expressing high IGF-1R activity [27] . Hartog et al. [28] pointed out the negative impact of IGF-1R overexpression on TNBC survival. To date, there are no published studies establishing a relation between IGF-1R expression and in vivo response of TNBC to an EGFR MoAB. However, the poor response to EGFR agent in low IGF-1R expressors could be explained by induced IGF-1R upregulation, part of an adaptive cellular response to EGFR blockade [29] .
Using Q-Finder algorithm, we identified a highly pCR-predictive biomarker combination yielding an 86% pCR rate in patients with both low CK8/18+ tumor fraction (<20%) and high EGFR expression (Q-score ≥80). CK8/18 is a marker for luminal tumors which downregulation promotes BC progression [30] . Tumors with a higher fraction of CK8/18+ cells were less sensitive to therapy mostly directed against basal-like TNBC. Recently, the basoluminal subtype was described, mixture of CK8/18+ with either CK5/14− or CK5/14+ cells, high frequency of HER2 gene amplification and shorter survival [15] . The importance of CK8/18 expression to predict pCR in TNBC needs confirmation.
So far, the pCR-predictive value of EGFR protein expression is unclear. In our study, high EGFR histoscore tumors (>80) were more therapy-sensitive, suggesting that a minimal target quantity might be necessary for EGFR MoAB activity. An 80-histoscore covers the situations from 80% tumor cells with weak EGFR expression (intensity 1) to at least 25% tumor cells with strong EGFR expression (intensity 3). As the main role of EGFR agents is enhancing CT sensitivity, our results indicate that a combination of EGFR agent and cytotoxics might be effective in TNBC, pending a critical level of EGFR expression.
In conclusion, panitumumab in combination with CT appears efficacious, with acceptable toxicity, as neoadjuvant therapy for operable TNBC. This study suggests that it is possible to predict high pCR rates in biologically defined subsets. Biomarkers such as CD8+ TIL, CK8/18 and EGFR could help define subpopulations sensitive to CT and EGFR MoAB. 
